← Back to Search

[^18F] FLuorthanatrace PET/CT for Ovarian Cancer

Phase 1

Recruiting

Led By Lilie L Lin

Research Sponsored by M.D. Anderson Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

History of known or suspected solid tumor.

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 4 years

Awards & highlights

Study Summary

This trial uses PET/CT scans with a radioactive tracer to find ovarian, fallopian tube, or primary peritoneal cancer cells.

Who is the study for?

This trial is for patients with solid tumors, such as ovarian, fallopian tube, or primary peritoneal cancer. Participants must have at least one tumor lesion of 1.0 cm visible on standard imaging. Pregnant or breastfeeding women and those unable to tolerate imaging procedures are excluded.Check my eligibility

What is being tested?

The study tests how well a radioactive tracer called Fluorine F 18 fluorthanatrace works in PET/CT scans for detecting tumor cells in various cancers. It's a phase I trial focused on the effectiveness of this novel radiotracer in detailed body imaging.See study design

What are the potential side effects?

As this is an imaging study using a radioactive tracer, potential side effects may include reactions to the tracer like rash or itching, discomfort from the PET/CT procedure, and exposure to radiation.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have or might have had a solid tumor in the past.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 4 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 4 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 4 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Poly (ADP-ribose) polymerase inhibitor (PARP)-1 activity as assessed by fluorine F 18 fluorthanatrace positron emission tomography/computed tomography

Secondary outcome measures

BRCA mutation status

Change in fluorine F 18 fluorthanatrace uptake measures after therapy

Incidence of adverse events

+1 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: Treatment (FDG PET/CT, [18F]FTT PET/CT)Experimental Treatment4 Interventions

Patients receive FDG IV and undergo FDG PET/CT scan over 20-30 minutes if they have not already had one per standard of care. At least 20-24 hours later, patients receive fluorine F 18 fluorthanatrace IV and undergo [18F]FTT PET/CT over 1 hour.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Positron Emission Tomography

2008

Completed Phase 2

~2240

Computed Tomography

2017

Completed Phase 2

~2720

Fludeoxyglucose F-18

2018

Completed Phase 2

~550

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

M.D. Anderson Cancer CenterLead Sponsor

2,972 Previous Clinical Trials

1,787,021 Total Patients Enrolled

47 Trials studying Ovarian Cancer

16,745 Patients Enrolled for Ovarian Cancer

National Cancer Institute (NCI)NIH

13,662 Previous Clinical Trials

40,925,773 Total Patients Enrolled

286 Trials studying Ovarian Cancer

73,766 Patients Enrolled for Ovarian Cancer

Lilie L LinPrincipal InvestigatorM.D. Anderson Cancer Center

4 Previous Clinical Trials

372 Total Patients Enrolled

Media Library

Fluorine F 18 Fluorthanatrace Clinical Trial Eligibility Overview. Trial Name: NCT03604315 — Phase 1

Ovarian Cancer Research Study Groups: Treatment (FDG PET/CT, [18F]FTT PET/CT)

Ovarian Cancer Clinical Trial 2023: Fluorine F 18 Fluorthanatrace Highlights & Side Effects. Trial Name: NCT03604315 — Phase 1

Fluorine F 18 Fluorthanatrace 2023 Treatment Timeline for Medical Study. Trial Name: NCT03604315 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the upper limit of participants being accepted in this trial?

"Indeed. Per the info available on clinicaltrials.gov, this medical investigation is currently recruiting participants. It was initially uploaded on December 18th 2018 and most recently modified August 24th 2022; 120 people are sought from 1 site."

Answered by AI

Could you elucidate on the potential risks of Fluorine F 18 Fluorthanatrace exposure?

"Limited evidence supports the safety and efficacy of Fluorine F 18 Fluorthanatrace, so it received a score of 1."

Answered by AI

Is it possible for new participants to join this research project?

"Information on clinicaltrials.gov affirms that this research is still actively attempting to recruit participants, with the original posting having been published December 18th 2018 and most recently updated August 24th 2022."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF

2018. "Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03604315.

All > Fallopian Tube Cancer > Recurrent Ovarian Cancer